Cho cells produce more and more new drugs!
Faricimab-svoa, a bispecific antibody indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration and diabetic macular oedema from Genentech was approved by the fda and by the European Medicines Agency in 2022 and is commercialized under the name of Vabysmo Vabysmo is a vascular endothelial growthfactor (VEGF) and angiopoietin-2 (Ang-2) inhibitor Vabysmo is for intravitreal injection. Are you involved in R&D on antibodies ? Are […]